Proteomic pattern of breast milk discriminates obese mothers with infants of delayed weight gain from normal-weight mothers with infants of normal weight gain

Christo Atanassov\(^1,2\), Etienne Viallemonteil\(^2\), Charlotte Lucas\(^3,4\), Marylise Perivier\(^1\), Stéphane Claverol\(^5\), Roland Raimond\(^2\) and Régis Hankard\(^6\)

\(^1\) CHU - La Milétrie, Poitiers, France
\(^2\) UMR-CNRS 7267, Université de Poitiers, France
\(^3\) Pédiatrie Multidisciplinaire-Nutrition de l’Enfant, CHU - La Milétrie, Poitiers, France
\(^4\) INSERM CIC 1402, Poitiers, France
\(^5\) Pôle Protéomique, Université Victor Segalen - Bordeaux 2, France
\(^6\) INSERM U1069, Université François Rabelais, Tours, France

\Keywords\n
breast milk; infant weight gain; maternal obesity; plgR; SELDI biomarker

\Correspondence\n
C. Atanassov, UMR CNRS 7267 “EBI”, Equipe SEVE, 3, rue Jacques Fort, Bât. B31, TSA 51106, 86073 Poitiers Cedex 9, France
Tel: + 33 5 49 45 49 87
E-mail: h.atanassov@chu-poitiers.fr

(Received 31 October 2018, revised 16 January 2019, accepted 8 February 2019)

doi:10.1002/2211-5463.12610

We previously reported that exclusively breastfed infants born to mothers with pregestational obesity gain less weight during the first month after birth than those born to mothers of normal pregestational weight [1]. This issue is potentially important since lower weight gain in breastfed infants of obese mothers might increase the risk of developing later obesity. Breast milk quality and quantity, together with breastfeeding practice, possibly influence infants’ feeding behavior, appetite control, and regulation of growth later in life. The issue of whether breast milk protein patterns from obese mothers differ in composition from those of non-obese mothers remains largely unexplored. Here, we established a breast milk proteomic pattern that discriminates obese mothers and infants with delayed weight gain at 1 month after birth from normal-weight mothers with infants of the same age and with normal weight gain. Obese mothers were matched to normal-weight mothers (n = 26; body mass index 33.5 ± 3.2 vs 21.5 ± 1.5 kg·m\(^{-2}\)). The mean weight gain of infants in the obese group at 1 month after birth was 430.8 g lower than that of the infants in the control group. Analysis of the breast milk delipidized fraction by surface-enhanced laser desorption/ionization on CM10 and Q10 arrays was followed by MS-assisted purification and LC-MS/MS microsequencing of a selected biomarker. We identified 15 candidate protein biomarkers, seven of which were overexpressed in the obese group and eight in the normal-weight group. One of the most significant candidate biomarkers, overexpressed in the obese group, was identified as a fragment of the sixth extracellular domain of the polymeric immunoglobulin receptor. Further structural identification of these candidate biomarkers and their validation in clinical assays may facilitate the development of a predictive immunoassay.

Abbreviations

AUC, area under the ROC curve; BMI, body mass index; EDM, expression difference mapping; PCA, principal component analysis; plgR, polymeric immunoglobulin receptor; ROC, receiver operating characteristic; SELDI, surface-enhanced laser desorption/ionization.
mothers might increase the risk of developing later obesity [2,3] through mechanisms of catch-up growth, such as observed in 5-year-old children whose body weight at birth is below normal [4]. Although the perception of inadequate milk supply by obese mothers was correlated to poor weight gain of their infants [1], and growth velocity in the first months of postnatal life was associated with later overweight and obesity [5], the issue is much more complex. Breast milk quality and quantity together with breastfeeding practice possibly influence infants feeding behavior, appetite control and regulation of growth later in life. A multitude of bioactive breast milk components must be taken into consideration such as oligosaccharides, polyunsaturated fatty acids, proteins and derived peptides [6–8], cytokines [9], and hormones [10]. For example, the presence of the anorexigenic hormone leptin in breast milk of non-obese mothers at 1 month of lactation was found to be negatively correlated with infants’ body mass index (BMI) at 18 and 24 months of age [11]. In this regard, we have recently reported that human milk leptin concentration was almost twice as high in obese mothers than in normal-weight mothers at 1 month postpartum [12]. Along with leptin, other yet unidentified milk components may be involved in this phenomenon.

The issue of whether breast milk protein patterns from obese mothers differ in composition from those of non-obese mothers remains largely unexplored. To that end, we compared breast milk protein patterns in fully breastfeeding women, either obese or normal weight, by surface-enhanced laser desorption/ionization (SELDI) ProteinChip technology. The latter allows rapid detection and semi-quantification of candidate protein biomarkers and facilitates their further purification in view of sequencing by MS.

Subjects, materials and methods

Participants and clinical study design

Mother and infant dyads were recruited in the university maternity hospitals of Poitiers and Châtellerault in western France. Obese mothers (BMI ≥ 30 kg·m⁻² before pregnancy) were matched for age (± 5 years), pregnancy status (first infant vs second or more), ethnic origin, and educational level with normal-weight mothers (18.5 ≤ BMI < 25 kg·m⁻²). Pairs of mothers with preexisting chronic or gestational diseases, smokers during pregnancy, twin pregnancies, children born prematurely, i.e. with a gestational age < 37 weeks of amenorrhea, with a low birth weight (< 3rd percentile for gestational age according to

reference curves from the French AUDIPOG study) [13] or hospitalized in the neonatal period were excluded. Only infants who remained exclusively breastfed at 1 month and their mothers participated in this study and the study was conducted according to the principles expressed in the Declaration of Helsinki. The CPP Ouest III ethics committee approved the protocol (7 September 2009). After having explained the study protocol to all participating mothers, a written consent was obtained. Participating mothers at 1 month postpartum and their infants were investigated in the department of INSERM ‘CIC 1402’ located in the university hospital center of Poitiers, CHU – La Milétrie. Clinical examination and collection of the data presented in Data S1 were carried out as described previously [12].

Breast milk

Milk was collected from the breast opposite to that suckled by the baby using an electric breast pump (‘Symphony’, Medela, Switzerland), immediately homogenized by vortexing, supplemented with a mix of protease inhibitors (Complete, EDTA-free; Roche Diagnostics, Mannheim, Germany) according to the provider’s protocol and stored at −80 °C. The samples were blind-coded, with the same identification number for each pair. After a low-speed centrifugation (1000 g, 20 min, 4 °C), the intermediate layer between the lipids on the surface and the cell debris pellet was aspirated and centrifuged again (18 000 g, 90 min, 4 °C). The total protein content of the aspirated intermediate layer (delipidized fraction) was determined by bicinchoninic acid assay (Pierce Biotechnology, Rockford, IL, USA).

ProteinChip array processing

Two types of SELDI ProteinChip ion-exchange arrays, Q10 and CM10, were assembled in a 96-well bioprocessor (Bio-Rad, Hercules, CA, USA) and preactivated for 30 min with their respective buffers (100 mM Tris/ HCl, pH 9.0 or 100 mM sodium acetate, pH 4.0). In the next step, 180 µL of the binding buffer for the respective array was mixed with 20 µL of prediluted delipidized milk fraction (previously adjusted to a final protein concentration of 0.5 mg·mL⁻¹ in all test samples) and further incubated for 60 min. All samples were tested in duplicate. After two washes with the binding buffers and one quick rinse with HPLC-grade water, the spots were loaded twice with 1 µL of saturated solution of sinapinic acid dissolved in 50% acetonitrile/0.5% trifluoroacetic acid (v/v). All steps were carried out at room temperature (18–20 °C), using a Micromix-5 platform shaker and a Biomek 3000 robot-pipetting workstation (Beckman-Coulter, Brea, CA, USA). The arrays were processed in a PCS 4000 ProteinChip Reader (Bio-Rad), which was
programmed in a positive ion mode and at ion acceleration potential of 20 kV.

For spectra processing, expression difference mapping (EDM) was carried out using PROTEINCHIP DATA MANAGER 3.0.7 software (Bio-Rad). After calibration and normalization of all spectra using the total ion current method, clusters of peaks with the same mass were defined at the following settings: signal-to-noise ratio (S/N; first pass), ≥ 5; minimum peak threshold, 20%; mass error, 0.3%; S/N (second pass), ≥ 2.

Statistics

Heat map hierarchical clustering, non-parametric Mann–Whitney test and receiver operating characteristic (ROC) curve analysis were applied for data analysis using the build-in PROTEINCHIP DATA MANAGER 3.0.7 package. In addition, paired t-test, ROC curve (PRISM version 5.01; GraphPad Software Inc., La Jolla, CA, USA) and principal component analysis (PCA; r-3.2.2; https://CRAN.R-project.org/doc/FAQ/R-FAQ.html; K. Hornik, 2016) were applied.

Protein purification procedures

Ion-exchange chromatography, reversed phase HPLC, tricine SDS/PAGE and MS-assisted control of protein purity were conducted as described previously [14].

Mass spectrometry analysis

Protein-containing bands were excised from the SDS/PAGE gel and treated with trypsin overnight at 37 °C. The peptide mixture was analyzed on a Dionex U-3000 Ultimate nano-LC system coupled to a nanospray LTQ-Orbitrap XL mass spectrometer (Thermo-Finnigan, San Jose, CA, USA). Data were acquired in a data-dependent mode alternating an MS scan survey over the range m/z 300–1700 and six MS/MS scans in an exclusion dynamic mode. MS/MS spectra were acquired using a 3 m/z units ion isolation window, a 35% relative collision energy, and a 30 s dynamic exclusion duration. Data were searched by SEQUEST through a PROTEOME DISCOVERER 1.3 interface (Thermo-Finnigan) against a subset of the 2012.09 version of UniProt database restricted to Homo sapiens (67 949 entries). The search parameters were as follows: mass accuracy of the monoisotopic peptide precursor and peptide fragments was set to 10 p.p.m. and 0.6 Da, respectively. Only b- and y-ions were considered for mass calculation. Oxidation of methionines (+16 Da) was considered as variable modification. Two missed tryptic cleavages were allowed. Peptide validation was performed and only ‘high confidence’ peptides were retained corresponding to a 1% false positive rate at peptide level.

Results

The present study relies on a careful selection of the studied subjects in the two groups by the following principal characteristics: close age and large BMI difference of the mothers; close values of the infants’ weight at birth and great delay in the infants’ weight gain after 1 month of breastfeeding. The difference between the means of infants’ weight gain of the normal-weight and the obese groups was 430.8 ± 97.1 g (95.2 ± 71.3 g in the normal-weight vs 521.7 ± 65.9 g in the obese

| Table 1. Principal characteristics of the mother–infant dyads. |
|-----------------|-----------------|-----------------|
|                  | Normal-weight   | Obese dyads     |
|                  | dyads (n = 26)  | (n = 26)        |
| Mothers          |                 |                 |
| Age (years)      | 30.7 ± 4.5      | 31.4 ± 4.8      |
| BMI (kg.m⁻²)     | 21.5 ± 1.5      | 33.5 ± 3.2      |
| Infants’ weight  |                 |                 |
| at birth (g)     | 3 462.5 ± 387.2 | 3 522.3 ± 566.7 |
| Infants’ weight  |                 |                 |
| at 1 month (g)   | 4 415.0 ± 465.4 | 4 044.0 ± 676.9 |
| Infants’ weight  |                 |                 |
| gain at 1 month  | 952.5 ± 363.6   | 521.7 ± 336.2   |
| Mean ± SD (g)    | 952.5 ± 71.3    | 521.7 ± 65.9    |

*Calculated difference in weight gain of 1-month-old infants of normal-weight and obese mothers: 430.8 ± 97.1 (P < 0.0001 at 95% CI by paired t-test); AUC = 0.82 (positive group – normal-weight).

| Table 2. Candidate biomarkers discriminating between obese and normal-weight groups. |
|-------------------------------|-----------------|-----------------|
| mz²a                         | ρb              | AUCc            | Array |
| 3825.29 ± 1.37               | 0.0002          | 0.75            | Q10   |
| 5225.37 ± 3.99               | 0.0004          | 0.72            | Q10   |
| 28107.69 ± 11.09             | 0.0065          | 0.32            | CM10  |
| 5159.45 ± 5.33               | 0.0087          | 0.67            | Q10   |
| 7150.22 ± 1.34               | 0.0171          | 0.67            | CM10  |
| 4470.78 ± 1.22               | 0.0227          | 0.36            | CM10  |
| 25702.09 ± 26.43             | 0.0227          | 0.37            | CM10  |
| 28292.76 ± 15.32             | 0.0267          | 0.36            | CM10  |
| 7255.14 ± 1.76               | 0.0281          | 0.67            | CM10  |
| 14183.01 ± 5.41              | 0.0282          | 0.31            | CM10  |
| 7142.37 ± 1.54               | 0.0290          | 0.63            | CM10  |
| 25000.21 ± 29.28             | 0.0306          | 0.66            | CM10  |
| 18450.82 ± 24.89             | 0.0314          | 0.35            | CM10  |
| 11730.86 ± 2.87              | 0.0388          | 0.37            | CM10  |
| 5255.59 ± 1.35               | 0.0388          | 0.36            | CM10  |

a The mass-to-charge ratios (m/z) corresponds to molecular masses expressed in Da (z = 1) ± SD.
b Significance of expression difference: 0.0002 < P < 0.04 at 95% CI (Mann–Whitney U test).
c In all AUC the obese group is selected as positive.
group). This weight gain in favor of infants of normal-weight mothers was significant when analyzed by paired t-test ($P < 0.0001$), and the area under the ROC curve (AUC) was 0.82 (Table 1).

The protein expression patterns of all samples (two groups of 26 each, normal weight and obese) were obtained on two types of ProteinChip arrays, CM10 and Q10, and the spectral data were submitted to several statistical analyses: univariate Mann–Whitney U test, ROC curve analysis, multivariate heat maps/hierarchical clustering, and PCA.

In the Mann–Whitney test, 15 proteins discriminating both groups were found (Table 2; Data S2). Of these, seven were overexpressed in the obese group (3825.3, 5159.4, 5225.4, 7142.4, 7150.1, 7255.1, 25000.2 Da) and eight in the normal-weight group (4470.8, 5255.6, 11730.9, 14183.0, 18450.8, 25702.1, 28107.7, 28292.8 Da). A heat map/hierarchical clustering of these 15 proteins allowed discrimination to some extent of the two studied groups with two clear-cut blocks, the first one encompassing 10 members of the normal-weight group, and the second one comprising seven members of the obese group (Fig. 1).

An additional variables factor map (PCA) of the expression differences of these 15 proteins confirmed the same tendency of separation in two groups, with seven proteins for the obese and eight for the normal-weight mothers. The first and the second PCA axis, corresponded respectively to 25.02% and 32.12% of the variance, revealing a strong positioning of the protein biomarkers for obese mothers in only one quadrant (upper right). Inversely, the positioning of protein biomarkers for normal-weight mothers extended over the three other quadrants, according to their PCA distribution (Fig. 2A). Furthermore, the individual factor map provided evidence for the two most marked proteins, namely ‘p5225’ (5225.4 Da) and, to a lesser extent, ‘p3825’ (3825.3 Da), both overexpressed in the group of obese mothers (Fig. 2B).

For this reason, p5225 was selected for further purification with a view to identification by sequencing. It was purified by several steps including ion exchange...
chromatography, reversed phase HPLC and Tricine SDS/PAGE. Throughout purification, all obtained fractions were systematically tested for the presence of the target p5225 protein by SELDI (the ion exchange chromatography fractions) and MALDI (the reversed phase HPLC fractions and those of passive elution from the Tricine SDS/PAGE gel slices). Eventually, the gel slice containing purified p5225 was trypsinized, submitted to LC-MS/MS, and the determined peptide masses were compared in silico to those in the proteome database of *H. sapiens*. In this way a 16-amino-acid sequence (ASVDSGSSEEQGSSR) was identified, which is part of the larger 49-amino-acid p5225 found by SELDI, i.e. REIENKAIQDPRLFAEEKAVADTRDQADGSRASVDSGSSEEQGSSRAL (Data S3). The BLAST analysis undoubtedly shows that p5225 lies within the extracellular region of the polymeric immunoglobulin receptor (pIgR). The main functions of pIgR are to mediate transcellular transport of dimeric IgA across mucosal epithelia and to serve as a precursor of the secretory component (pIgR:CAA51532.1; http://www.uniprot.org/uniprot/P01833).

**Discussion**

The innovative point of this study is the establishment of a discriminant breast milk proteomic pattern between dyads of obese mothers whose infants have delayed weight gain and normal-weight mothers whose infants of the same age have normal weight gain. This pattern consists of 15 candidate biomarkers with both a qualitative (m/z) and a semi-quantitative (intensity) feature. In our experiments, we used the delipidized milk fraction (whey) and SELDI methodology, which detects preferentially high abundance proteins. A search for low abundance proteins necessitates their prior enrichment in human milk by specific methods [15–17] and could possibly complement this pattern.

The identified MS/MS sequence of the p5225 candidate biomarker allows localization of it at position 591–640 of the full-length pIgR molecule, which corresponds to the sixth domain of pIgR [18,19]. Domain 6 of pIgR is involved in the enzymatic cleavage of pIgR and the release of a free secretory component into the intestinal lumen [19], and this may function as well in the epithelium of the mammary gland. Interestingly, the sequences of 10 amino acids flanking the N- and C-terminal ends of the intermediary highly conserved nine-amino-acid sequence at position 605–613 within domain 6 has been shown to exert opposite effects on pIgR cleavage, by enhancing and reducing cleavage efficiency, respectively. Since all breast milk samples in our experiments were supplemented, as soon as collected, with one of the most exhaustive combinations

---

**Fig. 2.** PCA of the 15 significant proteins (Table 2) denoted to as ‘v1–v15’. The tendency of separation is shown by green ellipses. Blue and red dots indicate individual data items of normal weight (N) and obese (O) mothers, respectively. The tendency of separation in two groups by the pIgR (‘v2’; panel A) is in line with the vertical axis between the two centers of gravity of the obese (‘O’) and normal weight (‘N’) groups (panel B). However, this tendency is not definite and can also be attributed to p3825 (‘v1’). Software used for the PCA: r package, version 3.2.2 (https://CRAN.R-project.org/doc/FAQ/R-FAQ.html; K. Hornik, 2016).
of protease inhibitors available (i.e. ‘Complete, EDTA-free’; Roche), the origin of the p5225 fragment supposes (a) enzymatic cleavage of the extracellular domain of pIgR on the apical surface of polarized epithelial cells [19], and (b) rapid enzymatic hydrolysis in mature milk that has overridden the protection of the protease inhibitors used. In the latter case, it is likely that full-length pIgR is very rapidly degraded during the first 20–30 min process of breast milk collection. This is corroborated by a recent study that pinpoints pIgR as one of the two human milk proteins that are most affected by enzymatic hydrolysis [20], albeit some enzymes still remain unidentified [19].

However, the relative abundance of the p5225 fragment detected by SELDI may not only be due to increased protease activity and rate of hydrolysis, but also reflect overexpression of the full-length pIgR and pertains to our main finding that mature breast milk of obese mothers which are fully breastfeeding their children may have a higher pIgR content than that of matched normal-weight mothers. The putative involvement of pIgR in the weight control of breastfed infants is corroborated by two independent functional studies on an animal model. In this latter regard transgenic experiments on mice have convincingly shown that the targeted overexpression of plgR in the mammary gland impairs the nutritional value of milk [21], which results in retarded growth and development of the newborn pups (regardless of whether they were transgenic or not) drinking this milk, eventually leading to death 2 weeks after birth [22]. These experiments provide a plausible explanation for a novel pIgR function deduced from our exploratory study, i.e. correlation of pIgR overexpression to some delay in the early infants’ weight gain. Moreover, qualitative analysis of transgenic murine milk has revealed that overexpression of plgR caused the loss of κ-casein and the appearance of serum amyloid A-1 (an acute inflammatory protein) [22]. The two latter studies imply that the loss of the first protein, the overexpression of the second, or a combination of both has caused growth disturbance of the suckling pups, but obviously the underlying pathogenesis is much more complex. It has been shown that the induction of plgR in the mammary gland affects expression of a much larger number of genes and their final protein products in milk, as documented by patterns of intestinal cell gene expression in breeding experimental schemes with plgR-sufficient and plgR-deficient mice [23].

Although tantalizing, our hypothesis of pIgR overexpression in obese mothers needs definite demonstration by more sophisticated methods, such as absolute MS quantification using internal standards. The reported proteomic SELDI pattern and the sequencing of the plgR biomarker open perspectives for further deciphering the complex multifactorial breast milk-mediated molecular cross-talk between mother and infant.

Acknowledgements

This study was supported by grants of the Ligue contre le Cancer-86 to CA (convention no. 2008/177) and PHRC Interrégional Grand-Ouest to RH (no. B91049-20). Special thanks to Prof. Pierre Ingrand, Dr Marie-Agnès Gaud, Dr Marine Frasquet from the CHU of Poitiers, Mrs Patricia Christin and Mrs Florence Compain from the Maternity Department of the Hospital Center of Châtellerault, Mrs Sonia Leroux, Mrs Elodie Rogeon and Dr Pierre-Jean Saulnier from INSERM CIC 1402, as well as to all involved families.

Conflict of interest

The authors declare no conflict of interest.

Author contributions

CL participated in the collection of breast milk samples within the frame of a clinical trial registered at the EudraCT Clinical Trials Registry (eudract.ema.europa.eu) as 2009-A00912-55. EV performed SELDI EDMI, MS-assisted purification of target proteins and statistical analysis. MP contributed to all SELDI and protein purification experiments. RR contributed to the statistical analysis. SC did the LC-MS/MS sequencing. RH organized and supervised the clinical part of the study (case-control criteria, mothers’ and infants’ parameters, breast milk collection), and participated in writing the manuscript. CA conceived the proteomic part of the study, conducted all SELDI and peptide purification experiments, analyzed the obtained data and wrote the manuscript.

References

1 Mok E, Multon C, Piguel L, Barroso E, Goua V, Christin P, Perez MJ and Hankard R (2008) Decreased full breastfeeding, altered practices, perceptions, and infant weight change of prepregnant obese women: a need for extra support. Pediatrics 121, e1319–e1324.
2 Baird J, Fisher D, Lucas P, Kleijn J, Roberts H and Law C (2005) Being big or growing fast: systematic review of size and growth in infancy and later obesity. BMJ 331, 929–936.
3 Monteiro POA and Victora CG (2005) Rapid growth in infancy and childhood and obesity in later life – a systematic review. *Obes Rev* 6, 143–154.

4 Ong KK, Ahmed ML, Emmett PM, Preece MA and Dunger DB (2000) Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. *BMJ* **320**, 967–971. Erratum in: *BMJ* **320**, 1244.

5 Regnault N, Botton J, Forhan A, Hankard R, Thiebaugeorges O, Hillier TA, Kaminski M, Heude B and Charles MA (2010) Determinants of early ponderal and statural growth in full-term infants in the EDEN mother-child cohort study. *Am J Clin Nutr* **92**, 594–602.

6 Lönnérerdal B (2013) Bioactive proteins in breast milk. *J Paediatr Child Health* **49** (Suppl 1), 1–7.

7 Lönnérerdal B (2014) Infant formula and infant nutrition: bioactive proteins of human milk and implications for composition of infant formulas. *Am J Clin Nutr* **99**, 712S–717S.

8 Wada Y and Lönnérerdal B (2014) Bioactive peptides derived from human milk proteins—mechanisms of action. *J Nutr Biochem* **25**, 503–514.

9 Garofalo R (2010) Cytokines in human milk. *J Pediatr* **156**, S36–S40.

10 Savino F, Benetti S, Liguori SA, Sorrenti M and Cordero Di Montezemolo L (2013) Advances on human milk hormones and protection against obesity. *Cell Mol Biol* **59**, 89–98.

11 Miralles O, Sánchez J, Palou A and Picó C (2006) A physiological role of breast milk leptin in body weight control in developing infants. *Obesity* **14**, 1371–1377.

12 De Luca A, Frasquet-Darrieux M, Gaud MA, Christin P, Boquien CY, Millet C, Herviou M, Darmaun D, Robins RJ, Ingrand P, Boquien CY, Millet C, Herviou M, Darmaun D, Robins RJ, Ingrand P et al. (2016) Higher leptin but not human milk macronutrient concentration distinguishes normal-weight from obese mothers at 1-month postpartum. *PLoS ONE* **11**, e0168568.

13 Mamelle N, Munoz F and Grandjean H (1996) Fetal growth from the AUDIPOG study. I. Establishment of reference curves. *J Gynaecol Obstet Biol Reprod (Paris)* **25**, 61–70.

14 Lanotte P, Perivier M, Haguenoer E, Mereghetti L, Burucoa C, Claverol S and Atanassov C (2013) Proteomic biomarkers associated with *Streptococcus agalactiae* invasive genogroups. *PLoS ONE* **8**, e54393.

15 Mangé A, Bellet V, Tuaillon E, Van de Perre P and Solassol J (2008) Comprehensive proteomic analysis of the human milk proteome: contribution of protein fractionation. *J Chromatogr B Analyt Technol Biomed Life Sci* **876**, 252–256.

16 Palmer DJ, Kelly VC, Smit AM, Kuy S, Knight CG and Cooper GJ (2006) Human colostrum: identification of minor proteins in the aqueous phase by proteomics. *Proteomics* **6**, 2208–2216.

17 Liao Y, Alvarado R, Phinney B and Lönnérerdal B (2011) Proteomic characterization of human milk whey proteins during a twelve-month lactation period. *J Proteome Res* **10**, 1746–1754.

18 Asano M, Takenouchi-Ohkubo N, Matsumoto N, Ogura Y, Nomura H, Suguro H and Moro I (2004) Multiple cleavage sites for polymeric immunoglobulin receptor. *Immunology* **112**, 583–589.

19 Sunagawa K, Omagari D, Nishiyama M, Asano M, Okudera M, Sugitani M, Nemoto N and Komiya K (2013) Distinct functional regions of the human polymeric immunoglobulin receptor. *Scand J Immunol* **78**, 339–344.

20 Khaldi N, Vijayakumar V, Dallas DC, Guerrero A, Wickramasinghe S, Smilowitz JT, Mediano JF, Lebrilla CB, Shields DC and German JB (2014) Predicting the important enzymes in human breast milk digestion. *J Agric Food Chem* **62**, 7225–7232.

21 de Groot N, van Kuik-Romeijn P, Lee SH and de Boer HA (1999) Over-expression of the murine polymeric immunoglobulin receptor gene in the mammary gland of transgenic mice. *Transgenic Res* **8**, 125–135. Erratum in: *Transgenic Res* **9**, 319.

22 de Groot N, van Kuik-Romeijn P, Lee SH and de Boer HA (2001) Over-expression of the murine plgR gene in the mammary gland of transgenic mice influences the milk composition and reduces its nutritional value. *Transgenic Res* **10**, 285–291.

23 Rogier EW, Frantz AL, Bruno ME, Wedlund L, Cohen DA, Stromberg AJ and Kaelzol CS (2014) Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression. *Proc Natl Acad Sci USA* **111**, 3074–3079.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Data S1. Clinical data.

Data S2. Spectral data.

Data S3. Full-length plgR, 16 AA peptide and 49 AA ‘p5225’.